Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch
This article was originally published in The Tan Sheet
Executive Summary
The degree of difficulty is tremendous for the first novel switch FDA approves, but it would provide a template others can follow. FDA’s interest in fostering innovative OTC switches could work in favor of proposals to make currently Rx ingredients indicated for a chronic condition available nonprescription.